Contract Service Directory

CPL





Company Headquarters

7600 Danbro Crescent
Mississauga, ON L5N6L6
Canada

Company Description

CPL is a leading contract development and manufacturing organization (CDMO) that provides product development services and commercial manufacturing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products. Our modern development, manufacturing and testing facilities are registered and audited with the FDA and Health Canada and have a solid record of regulatory compliance. Our product experience includes NDA's, ANDA's, 505b2, and OTC products, and we provide clinical trial material manufacturing through commercial product manufacturing. CPL has completed substantial investments in new filling and manufacturing technologies including new Symex mixing vessels. By offering a full-spectrum of partnership – from development to commercial production – CPL provides turnkey solutions and creates strategic relationships with our customers. To learn more about how CPL can support your product development and manufacturing needs, please visit our website: www.cplltd.com.

Contract Service Directory

    Related Content

    • THE CENTRE FOR CELL AND VECTOR PRODUCTION (CCVP)

      A Transparent and Flexible Approach to Manufacturing

    • Breaking News | CRO News | Promotions & Moves
      Parexel Adds Experts to Regulatory Consulting Group

      Parexel Adds Experts to Regulatory Consulting Group

      Four new hires from U.S. FDA and MHRA will serve as technical vice presidents
      12.10.19

    • Breaking News | Drug Development | Trials & Filings
      SK Bio Gains FDA Approval for XCOPRI

      SK Bio Gains FDA Approval for XCOPRI

      Marks the first time a Korean company has independently brought a compound from discovery to U.S. FDA approval
      11.25.19


    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19


    • Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      FPP Inks ANDA Generic Deal

      FPP Inks ANDA Generic Deal

      Upon approval, manufacturing will be performed by the CDMO Novocol.
      10.21.19


    • Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News | Injectables
      Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product

      Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product

      ANDA holder Sagent will sell, market and distribute the drug product in the U.S.
      09.23.19

    • Regulatory Affairs
      Quality Metrics Feedback

      Quality Metrics Feedback

      A look at FDA’s Quality Metrics Initiative, a complicated issue for all of pharma stakeholders
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 09.16.19

    • Breaking News | Clinical Trials | Industry News | Inspections | QA/QC
      FDA Extends CRADA with CluePoints

      FDA Extends CRADA with CluePoints

      Aims to further explore a data-driven approach to quality oversight in clinical trials
      09.11.19


    • cGMP Manufacture | Collaborations & Alliances
      NIIMBL, FDA to Advance Innovation in Bio Manufacturing

      NIIMBL, FDA to Advance Innovation in Bio Manufacturing

      CRADA enables FDA and NIIMBL to support investments in regulatory science research, and training needed to foster advanced manufacturing innovations
      08.01.19

    • cGMP Manufacture | Industry News | Regulatory Affairs
      FDA Posts FY2020 GDUFA Fees

      FDA Posts FY2020 GDUFA Fees

      The fee for U.S. CMO FDF facilities will drop 7% next year; negotiation efforts led by PBOA
      07.25.19

    • Trials & Filings
      FDA Accepts RedHill Biopharma’s NDA for Talicia

      FDA Accepts RedHill Biopharma’s NDA for Talicia

      Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
      07.16.19


    • Extractables and Leachables | Laboratory Testing
      The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

      The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

      Andrew Kolbert of Avomeen discusses FDA oversight of E&L testing, complications that arise, and the expertise needed to keep up with changing quality standards
      Kristin Brooks, Contract Pharma 07.11.19

    • SunGen Pharma, Athenex Pharma Partner for Bivalirudin Launch

      SunGen Pharma, Athenex Pharma Partner for Bivalirudin Launch

      An anticoagulant injection with 2018 US Market Sales at $81.8M according to IQVIA data
      06.27.19

    • Trials & Filings
      Sierra’s Momelotinib Granted FDA Fast Track Designation

      Sierra’s Momelotinib Granted FDA Fast Track Designation

      Underscores potential for momelotinib to address unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor
      06.19.19